- Home
- MCRB vs AGEN Comparison
MCRB vs AGEN Comparison
Compare MCRB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- AGEN
- Stock Information
- Founded
- MCRB 2010
- AGEN 1994
- Country
- MCRB United States
- AGEN United States
- Employees
- MCRB N/A
- AGEN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRB Health Care
- AGEN Health Care
- Exchange
- MCRB Nasdaq
- AGEN Nasdaq
- Market Cap
- MCRB 165.3M
- AGEN 142.8M
- IPO Year
- MCRB 2015
- AGEN 2000
- Fundamental
- Price
- MCRB $15.91
- AGEN $4.48
- Analyst Decision
- MCRB Hold
- AGEN Buy
- Analyst Count
- MCRB 4
- AGEN 2
- Target Price
- MCRB $73.67
- AGEN $14.50
- AVG Volume (30 Days)
- MCRB 245.4K
- AGEN 404.8K
- Earning Date
- MCRB 11-12-2025
- AGEN 11-11-2025
- Dividend Yield
- MCRB N/A
- AGEN N/A
- EPS Growth
- MCRB N/A
- AGEN N/A
- EPS
- MCRB 10.22
- AGEN N/A
- Revenue
- MCRB N/A
- AGEN $101,706,000.00
- Revenue This Year
- MCRB N/A
- AGEN $26.25
- Revenue Next Year
- MCRB N/A
- AGEN N/A
- P/E Ratio
- MCRB $1.62
- AGEN N/A
- Revenue Growth
- MCRB N/A
- AGEN N/A
- 52 Week Low
- MCRB $6.53
- AGEN $1.38
- 52 Week High
- MCRB $24.67
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- MCRB 44.26
- AGEN 46.23
- Support Level
- MCRB $17.00
- AGEN $4.12
- Resistance Level
- MCRB $24.67
- AGEN $5.20
- Average True Range (ATR)
- MCRB 2.01
- AGEN 0.29
- MACD
- MCRB -0.50
- AGEN 0.07
- Stochastic Oscillator
- MCRB 15.94
- AGEN 34.55
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).